Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 18/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 13/20 | 1.00 |
| ▸ | PDE2A | O00408 | 6/20 | 0.86 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.83 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.83 |
| ▸ | PTGFR | P43088 | 1/20 | 0.83 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.83 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.83 |
| ▸ | PTGIR | P43119 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990414 | 0.96 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL6469510 | 0.93 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL989833 | 0.93 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL1255195 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL1255151 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL6521839 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL5824247 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL990595 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL990988 | 0.91 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL1900503 | 0.91 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019022-B2 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA & CO. (CA) | 2006-03-28 | — | — | US | claimed |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA LTD. (CA) | 2005-07-14 | — | — | US | claimed |
| US-7019022-B2 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA & CO. (CA) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | PTGIR, PTGDR, PTGDR2 | PTGDR 2/4885TBXA2R 10/4885PDE2A 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.